Tennant Company Faces Securities Probe After 23% Stock Plunge on Missed Guidance

BenzingaBenzinga
|||5 min read
Key Takeaway

Schall Law Firm investigates Tennant Company ($TNC) for securities violations after 23.4% stock decline following missed 2025 earnings due to ERP system problems.

Tennant Company Faces Securities Probe After 23% Stock Plunge on Missed Guidance

Tennant Company Faces Securities Probe After 23% Stock Plunge on Missed Guidance

The Schall Law Firm has launched an investigation into $TNC for potential securities law violations following a dramatic earnings miss and subsequent stock collapse. On February 23, 2026, Tennant Company reported 2025 full-year financial results that significantly underperformed consensus expectations on both revenue and earnings per share. The company attributed the shortfall to operational disruptions stemming from implementation problems with its new enterprise resource planning (ERP) system, which created prolonged delays for customers. The disclosure triggered a sharp market reaction, with Tennant's stock tumbling 23.4% in the session immediately following the announcement—a rare single-day decline that has now attracted regulatory scrutiny from the litigation firm.

The Earnings Miss and ERP System Failures

Tennant Company's 2025 financial performance fell materially short of market expectations, though the company did not disclose the specific magnitude of the revenue and earnings per share misses in the available summary. What the company did clarify was the root cause: operational challenges related to the implementation of a new ERP system. Such ERP transitions are critical infrastructure projects that touch nearly every function within a manufacturing and distribution-focused business like Tennant, which specializes in cleaning equipment and related products.

The timing and severity of the miss raises important questions in the investigative context:

  • System implementation delays created customer fulfillment bottlenecks
  • Prolonged customer delays suggest the ERP problems persisted longer than anticipated
  • Consensus estimates were materially missed, implying either forecasting errors or disclosure gaps
  • Stock reaction magnitude (23.4% decline) signals investors viewed the explanation as materially concerning

ERP implementations are well-documented operational risks in corporate America. When major system transitions go awry, they can cascade through supply chains, delay revenue recognition, and create inventory management challenges. The fact that Tennant attributed its earnings miss to these technical issues rather than market demand weakness suggests the company faced internal execution problems rather than external market deterioration.

Market Context and Industry Backdrop

Tennant Company operates in the industrial cleaning equipment and supplies sector, an industry that has faced headwinds in recent years from competitive pressures and shifting customer preferences toward outsourced cleaning services. The company's struggles with ERP implementation must be viewed against this competitive backdrop.

For investors, the concerning element here extends beyond the operational miss itself. The investigation by the Schall Law Firm—a firm specializing in securities litigation—suggests the legal question centers on whether Tennant adequately disclosed known risks related to the ERP implementation before the February 2026 announcement. Securities law violations typically hinge on material omissions or misleading statements, not merely disappointing operational results.

Key market context considerations:

  • ERP risk disclosure: Did Tennant adequately warn investors about implementation risks in prior quarterly filings?
  • Magnitude of miss: The 23.4% stock decline suggests the market viewed the miss as surprising and material
  • Timing of disclosure: Implementation problems typically emerge gradually—why was the severity apparent only at year-end results?
  • Industry competitiveness: Operational disruptions create competitive advantages for better-managed rivals

The cleaning equipment sector includes larger competitors like Nilfisk and various regional players, making operational efficiency and customer service critical differentiation factors. A prolonged ERP-related service disruption could have caused customer defection to competitors.

Investor Implications and Legal Risk

For current and recent shareholders of $TNC, the implications are significant on multiple fronts. The 23.4% single-session decline already inflicts substantial losses on holders. Beyond the immediate price impact, the securities investigation introduces additional uncertainty regarding potential legal liabilities, regulatory penalties, or management changes.

The investigation's scope will likely examine:

  • Pre-announcement disclosures: Quarterly reports and earnings calls from 2024 and early 2025 for ERP risk warnings
  • Management knowledge: When did executives become aware of the severity of implementation problems?
  • Analyst communications: Any guidance provided to investors about 2025 performance expectations
  • Insider trading activity: Whether officers sold shares before the negative announcement

Historically, securities investigations stemming from missed earnings guidance rarely result in criminal charges but can lead to civil settlements requiring disgorgement of executive compensation, substantial shareholder class action settlements, and management turnover. The Schall Law Firm investigation suggests shareholders are already mobilizing to pursue a class action lawsuit against the company and potentially its officers and directors.

For the broader market, this case exemplifies the risks associated with major enterprise system implementations—a lesson that has been underscored repeatedly in recent years, from retail bankruptcies to technology company write-downs caused by failed modernization projects.

Forward-Looking Implications

Tennant Company now faces a complex period navigating both operational recovery and legal exposure. Management must stabilize the ERP system implementation while the company deals with litigation discovery, potential regulatory inquiries, and shareholder pressure. The stock's 23.4% decline reflects the severity of lost investor confidence.

For potential class action participants, the Schall Law Firm's investigation offers a formal avenue to pursue claims for securities fraud based on alleged pre-announcement disclosures that failed to adequately convey ERP implementation risks. The outcome of this investigation could significantly impact Tennant's capital structure, insurance coverage, and management roster in the months ahead. Investors should monitor regulatory filings and legal developments closely as this situation unfolds.

Source: Benzinga

Back to newsPublished Mar 1

Related Coverage

GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
Investing.com

D-Wave's 44% Plunge Masks Quantum Leap: Growth Story vs. Valuation Reality

D-Wave ($QBTS) fell 44% in 2026 despite strong bookings exceeding 2025 totals and $30M in major deals. Analysts see 132% upside, but 237x sales valuation remains extreme.

QBTS
GlobeNewswire Inc.

OneMain Holdings Faces Multi-State Securities Probe Over Alleged Lending Fraud

Pomerantz Law Firm investigates $OMF following multi-state lawsuit alleging deceptive lending practices. Stock tumbles 5.38% on fraud allegations.

OMF
GlobeNewswire Inc.

Boston Scientific Faces Securities Fraud Lawsuit Over Overstated EP Growth Claims

Boston Scientific faces class action lawsuit alleging material misstatements about electrophysiology growth. Stock fell 17.6% after disclosing slower market growth and competitive pressures.

BSX
GlobeNewswire Inc.

Nektar Therapeutics Faces Class Action Over Failed Trial Data Disclosure

Pomerantz LLP filed securities fraud class action against Nektar Therapeutics, alleging false statements about clinical trial enrollment procedures led to trial failure and stock decline.

NKTR
GlobeNewswire Inc.

Pomerantz Files Securities Fraud Suit Against $INO Over FDA Approval Misstatements

Pomerantz LLP sues Inovio Pharmaceuticals for alleged securities fraud over FDA approval misstatements. Stock fell 3.1% and 24.45% following manufacturing delays and accelerated approval rejection.

INO